Novel, high-yield red blood cell production methods from CD34-positive cells derived from human embryonic stem, yolk sac, fetal liver, cord blood, and peripheral blood

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The current supply of red blood cells expressing rare blood groups is not sufficient to cover all the existing transfusion needs for chronically transfused patients, such as sickle cell disease homozygous carriers, because of alloimmunization. In vitro production of cultured red blood cells is slowly emerging as a possible complement to the existing collection-based red blood cell procurement system. The yield of cultured red blood cells can theoretically be maximized by amplifying the stem, progenitor, or precursor compartment. Here, we combined methods designed to expand these three compartments to optimize the yield of cultured red blood cells and found that exposing CD34+ cells to a short pulse of cytokines favorable for erythroid differentiation prior to stem cell expansion followed by progenitor expansion produced the highest yield of erythroid cells. This novel serum-free red blood cell production protocol was efficient on CD34+ cells derived from human embryonic stem cells, 6 -8-week yolk sacs, 16 -18-week fetal livers, cord blood, and peripheral blood. The yields of cells obtained with these new protocols were larger by an order of magnitude than the yields observed previously. Globin expression analysis by high-performance liquid chromatography revealed that these expansion protocols generally yielded red blood cells that expressed a globin profile similar to that expected for the developmental age of the CD34+ cells.

Original languageEnglish (US)
Pages (from-to)604-614
Number of pages11
JournalStem cells translational medicine
Volume1
Issue number8
DOIs
StatePublished - 2012

Fingerprint

Yolk Sac
Fetal Blood
Erythrocytes
Liver
Globins
Erythroid Cells
Sickle Cell Anemia
Blood Group Antigens
Human Embryonic Stem Cells
Stem Cells
High Pressure Liquid Chromatography
Cytokines
Serum

Keywords

  • Adult stem cells
  • Embryonic stem cells
  • Erythroid
  • Fetal human liver
  • Hematopoiesis

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Medicine(all)

Cite this

@article{3224d05384814ca59d1f3480fa1ead01,
title = "Novel, high-yield red blood cell production methods from CD34-positive cells derived from human embryonic stem, yolk sac, fetal liver, cord blood, and peripheral blood",
abstract = "The current supply of red blood cells expressing rare blood groups is not sufficient to cover all the existing transfusion needs for chronically transfused patients, such as sickle cell disease homozygous carriers, because of alloimmunization. In vitro production of cultured red blood cells is slowly emerging as a possible complement to the existing collection-based red blood cell procurement system. The yield of cultured red blood cells can theoretically be maximized by amplifying the stem, progenitor, or precursor compartment. Here, we combined methods designed to expand these three compartments to optimize the yield of cultured red blood cells and found that exposing CD34+ cells to a short pulse of cytokines favorable for erythroid differentiation prior to stem cell expansion followed by progenitor expansion produced the highest yield of erythroid cells. This novel serum-free red blood cell production protocol was efficient on CD34+ cells derived from human embryonic stem cells, 6 -8-week yolk sacs, 16 -18-week fetal livers, cord blood, and peripheral blood. The yields of cells obtained with these new protocols were larger by an order of magnitude than the yields observed previously. Globin expression analysis by high-performance liquid chromatography revealed that these expansion protocols generally yielded red blood cells that expressed a globin profile similar to that expected for the developmental age of the CD34+ cells.",
keywords = "Adult stem cells, Embryonic stem cells, Erythroid, Fetal human liver, Hematopoiesis",
author = "Olivier, {Emmanuel N.} and Caihong Qiu and Bouhassira, {Eric E.}",
year = "2012",
doi = "10.5966/sctm.2012-0059",
language = "English (US)",
volume = "1",
pages = "604--614",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "8",

}

TY - JOUR

T1 - Novel, high-yield red blood cell production methods from CD34-positive cells derived from human embryonic stem, yolk sac, fetal liver, cord blood, and peripheral blood

AU - Olivier, Emmanuel N.

AU - Qiu, Caihong

AU - Bouhassira, Eric E.

PY - 2012

Y1 - 2012

N2 - The current supply of red blood cells expressing rare blood groups is not sufficient to cover all the existing transfusion needs for chronically transfused patients, such as sickle cell disease homozygous carriers, because of alloimmunization. In vitro production of cultured red blood cells is slowly emerging as a possible complement to the existing collection-based red blood cell procurement system. The yield of cultured red blood cells can theoretically be maximized by amplifying the stem, progenitor, or precursor compartment. Here, we combined methods designed to expand these three compartments to optimize the yield of cultured red blood cells and found that exposing CD34+ cells to a short pulse of cytokines favorable for erythroid differentiation prior to stem cell expansion followed by progenitor expansion produced the highest yield of erythroid cells. This novel serum-free red blood cell production protocol was efficient on CD34+ cells derived from human embryonic stem cells, 6 -8-week yolk sacs, 16 -18-week fetal livers, cord blood, and peripheral blood. The yields of cells obtained with these new protocols were larger by an order of magnitude than the yields observed previously. Globin expression analysis by high-performance liquid chromatography revealed that these expansion protocols generally yielded red blood cells that expressed a globin profile similar to that expected for the developmental age of the CD34+ cells.

AB - The current supply of red blood cells expressing rare blood groups is not sufficient to cover all the existing transfusion needs for chronically transfused patients, such as sickle cell disease homozygous carriers, because of alloimmunization. In vitro production of cultured red blood cells is slowly emerging as a possible complement to the existing collection-based red blood cell procurement system. The yield of cultured red blood cells can theoretically be maximized by amplifying the stem, progenitor, or precursor compartment. Here, we combined methods designed to expand these three compartments to optimize the yield of cultured red blood cells and found that exposing CD34+ cells to a short pulse of cytokines favorable for erythroid differentiation prior to stem cell expansion followed by progenitor expansion produced the highest yield of erythroid cells. This novel serum-free red blood cell production protocol was efficient on CD34+ cells derived from human embryonic stem cells, 6 -8-week yolk sacs, 16 -18-week fetal livers, cord blood, and peripheral blood. The yields of cells obtained with these new protocols were larger by an order of magnitude than the yields observed previously. Globin expression analysis by high-performance liquid chromatography revealed that these expansion protocols generally yielded red blood cells that expressed a globin profile similar to that expected for the developmental age of the CD34+ cells.

KW - Adult stem cells

KW - Embryonic stem cells

KW - Erythroid

KW - Fetal human liver

KW - Hematopoiesis

UR - http://www.scopus.com/inward/record.url?scp=84872117942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872117942&partnerID=8YFLogxK

U2 - 10.5966/sctm.2012-0059

DO - 10.5966/sctm.2012-0059

M3 - Article

VL - 1

SP - 604

EP - 614

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 8

ER -